56
Participants
Start Date
January 31, 2025
Primary Completion Date
July 31, 2025
Study Completion Date
August 31, 2025
Tranexamic Acid (IV)
The intervention is administered as a clear, colorless solution infusion. The dosage administered is a 1 gram intravenous (IV) push, delivered immediately before starting the Aquablation therapy. The administration of TXA occurs only once, as a single dose preoperatively.
Placebo
Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
Kaiser Permanente Los Angeles Medical Center, Los Angeles
Kaiser Permanente
OTHER